Biotin results in sustained improvement of disability in progressive MS.
Biotin is a cofactor for energy metabolism in the Kreb cycle, providing theoretical benefits related to axonal function, degeneration, and repair. To test the effects of high-dose biotin (MD1003) on progressive multiple sclerosis (MS), researchers conducted a 12-month randomized, double-blinded, placebo-controlled, manufacturer-sponsored multicenter trial. They randomized 154 patients 2:1 to MD1003 or placebo. Patients were 18 to 75 years old, had Expanded Disability Status Scale (EDSS) scores of 4.5 to 7.0, and met criteria for secondary progressive or primary progressive MS.
At month 9, 12.6% of patients had improvement in disability, confirmed at month 12. Of the 13 improved participants, 2 improved on both EDSS and 25-foot timed walk (25…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)